The Microcap Basement | Stock Discussion Forums

SiliconInvestor

register

Microcap & Penny Stocks | The Microcap Basement

Previous 10 | Next 10

From: atm_prophet	5/4/2010 2:15:01 PM
	of 4096

PSID HOT ALERT BUY RIGHT NOW IMO.... Here is the scoop Alert: Partnership News Pending PDF \| Print \| E-mail Written by Staff and Wire Reports Tuesday, 04 May 2010 10:06 There are some news developments to report regarding our earlier watchlist alert: PositiveID Corporation (Nasdaq: PSID) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge market that the test would open up. As we reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a patient’s exhaled breath. POSITIVEID 1.46 +0.04 (+2.82%) Intraday 3 Month 6 Month 1 Year It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company’s patent-pending technology. Industry sources say a significant partnership may be very close to completion and public announcement. In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading. Full Press Released Report coming to BioMedReports this afternoon.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: RikRichter	5/10/2010 10:53:53 PM
	of 4096

PLBI 0.007 - Adult stem cell news: Today's significant PR NEWS for RNL BIO has positive implications for PLBI/Regenobody affiliation: RNL Bio Opens Special Clinic for Stem Cell Therapy in Japan 2010-05-10 01:26:06 RNL Bio, a Seoul-based biotech firm, opens its Japanese branch ‘Kyoto Bedesta Clinic’ on Friday, a world’s first special hospital using the adult stem cell in treatment for those who suffer from cancer and autoimmune disease. The clinic in Kyoto is expected to provide the medical service by tapping into RNL’s cutting-edge technology in cultivating stem cells in massive scale, thanks to the flexibility in Japanese government’s policy on advanced technology. S. Korea’s leading biotech company explained that it is meaningful to establish such a hospital with the Korea's medical technology onto Japan, the country well-known for its advanced level in medicine. Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the body actually attacks its own cells. “Kyoto Bedesta Clinic is going to fully utilize the RNL Bio’s stem cell therapy which has been proven to be secured and effective,” said an official from RNL Bio. RNL Bio uses stem cells taken from one’s own fat tissues. After the stem cells have been isolated, the cell expansion process takes a minimal amount of stem cells and copies them identically until there are millions and even billions. These stem cells, the patient’s own, are then injected back into them for various degenerative diseases such as arthritis, cardiovascular disease and spinal cord injury. “Kyoto is the Japan’s largest tourism city with 1,000 visitors annually and it is going to lead the medical-tourism market by combining the cutting-edge technology in medical field with the city image as the luxury tourism city,” said the official,” said the official. “Since the patients with autoimmune disease have little difficulty in movement, they hardly need to be hospitalized. Therefore, the synergy effect can be maximized by offering tourism service during the stem cell therapy for about a month.” kirimi99@ajnews.co.kr [???? ajnews.co.kr] ???? ????

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

From: RikRichter	5/13/2010 9:49:48 AM
	of 4096

CONX.ob 0.1398(CORGENIX MEDICAL)turns a quarterly profit of $81K: Corgenix Reports Third Quarter Fiscal 2010 Financial Results -- Sales increase 8.1% vs. prior year and Company achieves net income for the quarter vs. substantial loss in prior year -- Corgenix Medical Corporation On Thursday May 13, 2010, 9:15 am DENVER, May 13 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board:CONX.ob - News), a worldwide developer and marketer of diagnostic test kits, today filed its 3rd quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues showed an 8.1% increase for the quarter and a 2.8% increase for the nine months ended March 31, 2010, in addition to a marked turnaround in the bottom line results. Some of the results highlighted by the report are as follows: •Sales increased 8.1% for the quarter vs. the prior year to almost $2.2 million •EBIDTA increased almost 29% for the current nine month period vs. the prior year •Net income improved to $81,175 in the current quarter from a $454,374 net loss in the prior year's comparable quarter Douglass Simpson, Corgenix CEO and President, stated, "We are very pleased with our quarter and the nine month results. The nice growth in sales combined with ongoing control of operating expenses, cost of goods sold, and interest expense resulted in positive net income for the quarter and essentially reaching the break-even point for the current 9 months, a $1.1 million improvement over the prior year." Third quarter 2010 Conference Call Details Corgenix invites all those interested in hearing management's discussion of third quarter results to join a shareholders conference call on Thursday, May 13, 2010, at 4:00 PM EDT (2:00 PM MDT). Interested parties can join the call by dialing (800) 862-9098. International participants may access the call by dialing +1 785-424-1051. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 753-0348 for U.S. participants and +1 402-220-2672 for international participants. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at corgenix.com Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements. SUMMARY OF FINANCIAL HIGHLIGHTS ($000 of U.S. dollars except shares outstanding and per share amounts) CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES OPERATIONAL DATA (in thousands) Three Months Ended Nine Months Ended March 31, 2010 March 31, 2009 March 31, 2010 March 31, 2009 (unaudited) (unaudited) (unaudited) (unaudited) Net sales $2,196 $2,032 $6,200 $6,029 Gross profit $1,226 $1,144 $3,416 $3,404 Total operating expenses $1,080 $1,205 $3,174 $3,616 Operating income (loss) $146 $(61) $242 $(211) Net income (loss) $81 $(454) $(9) $(1,063) Basic and diluted income (loss) per share $0.00* $(0.02) $(0.00)* $(0.04) Diluted shares outstanding 31,035,354 30,286,922 30,789,725 30,219,233 *Less than $0.01 per share SUMMARY BALANCE SHEET DATA (in thousands) March 31, 2010 (unaudited) June 30, 2009 (audited) Cash $ 488 $ 785 Working capital 2,091 2,013 Total assets 6,446 6,906 Long-term debt 547 744 Total stockholders' equity 3,105 3,113 Copyright © 2010 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: RikRichter	5/13/2010 9:58:32 AM
	of 4096

PLBI 0.011 favorable news on capital structure for this soon-to-be adult stem cell therapy company: PLBI/RegenoBody Announces Restructure of Convertible Preferred :01 AM ET 5/13/10 \| GlobeNewswire Proton Laboratories, Inc. (Pink Sheets:PLBI) announced today that Armando Casciati has signed and authorized the filing of an amendment to the Articles of Incorporation of the Company whereby his Series B Preferred Convertible Stock rights are changed. The change will eliminate his right to convert his 19,600,000 preferred shares into 1,000 shares of common for each preferred and will essentially grant him a super voting share holding position which will be able to convert into 55% of the common stock when combined with his common holdings. As of the date of this release, the conversion right would not affect any shareholders since Mr. Casciati currently owns approximately 70% of the issued common shares currently outstanding. In addressing this matter Mr. Casciati stated, "It was never my intent to have the Preferred Shares designated in the manner that they were issued. Former management had authorized and filed the designation as it was shown on our information statement. This new amendment and designation corrects the agreement that was made at the time of our being acquired by Proton Laboratories, Inc. and eliminates the huge overhang in the market that the prior designation created. The Amendment was filed last week and should be available for retrieval in the next 7 days." About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A: RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world today. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists, in conjunction with RNL Bio, have been regarded as the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care. About RNL Bio Company LTD: RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with state-of-the-art GMP facility, RNL is publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry. FORWARD-LOOKING STATEMENT: This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the company undertakes no obligation to update such statements. This news release was distributed by GlobeNewswire, www.globenewswire.com SOURCE: Proton Laboratories, Inc. CONTACT: Proton Laboratories, Inc. Investor Relations Tyler Cornell 631-765-8763

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: atm_prophet	5/14/2010 7:50:57 PM
	of 4096

SEE PREVIOUS POST WHEN I POSTED AT $2.02 less than 30 days ago 4/22/2010 12:23:26 PM PREVIOUS MESSAGE: NBS NEW STOCK FOR BOARD ($2.02 per share) Here is the deal: #1) AMEX - FULLY LISTED REPORTING COMPANY #2) Share Structure: Shares Outstanding 43.9 M Institutional Ownership 0.23% Number of Floating Shares 42.3 M Short Interest as % of Float 0.04% Huge Insider Buys: #3) Insider Transaction History On 10/30/09 over 20 million Dollar purchase at $2.04 per share. (HIGHER THAN CURRENT PRICE!) You can look up all of them but note just this one: 10/30/09 Rimasia Capital Partners Purchase 10,458,000 2.04 – 2.04 11,458,000 $21.3 M COMPANY PROFILE: NBS Company OverviewCompany Contact Headquarters: Suite 450, 420 Lexington Avenue, New York, NY 10170 Web Address: neostem.com NeoStem, Inc. (NeoStem) is a international biopharmaceutical company with global research and development capabilities and operations in three business units: U.S. adult stem cells, China adult stem cells and China pharmaceuticals, primarily antibiotics. In the United States the Company is a provider of adult stem cell collection, processing and storage services enabling healthy individuals to donate and store their stem cells for personal therapeutic use. Similar to the banking of cord blood, pre-donating cells at a younger age helps to ensure a supply of one's own stem cells should they be needed for future medical treatment. The Company's network of United States adult stem cell collection centers is focused primarily on the Southern California and Northeast markets. On October 30, 2009, NeoStem completed the merger with China Biopharmaceuticals Holdings, Inc. #5) RUMORS: FROM BIOMED WEBSITE: We have held off announcing the name of the company until today because we have been actively chasing a rumor that, if confirmed within the next three or so days, could easily send shares into the multiple dollar range. Positron Corporation (OTC BB: POSC.OB) has been around for over 25 years, but is now quickly evolving to the next level. Recently, they became the recipient of the “2010 Frost & Sullivan North American Molecular Imaging Systems New Product Innovation Award” Frost & Sullivan is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies. The New Product Innovation Award is a prestigious recognition of Positron Corporation’s accomplishments in the Integrated Cardiac Imaging Tools sector. An unbiased, 3rd party recognition will provide a profound impact in enhancing the brand value and thereby accelerating the growth of Positron Corporation’s diagnostic process potential in cardiology. See the chart below to see previous winners of the Frost & Sullivan award. Now in 2010 Positron has begun selling its Attrius PET™ scanner and will be launching its new proprietary product, the Nuclear Cardio-Assist®- a device that is a “virtual compound pharmacy” located on site at the physician’s office to dispense the radiopharmaceutical as a patient specific dose. This device will enable the company (and others) to sell radiopharmaceuticals direct to the nuclear cardiology facilities, alleviating the need for a centralized nuclear pharmacy and the antiquated distribution that it entails. Our sources tell us that within days we may hear news of either a partnership or buy-out involving this very much undiscovered, but highly impressive OTC company and a $25 billion NYSE traded company. We should have more exclusive details about that big news item in this space by Friday. It will follow tomorrow's fully press-released special report and interview with the CEO of the company. Last year, Positron achieved a major milestone, as its joint venture with Neusoft Medical Systems of China received FDA 510k approval on the “Attrius” PET scanner. The event signaled the beginning of Positron’s ability to market and sell its state of the art cardiac PET scanner, the Attrius, in the United States. In addition, the company's Cardio-Assist® will reshape the radiopharmaceutical distribution in the nuclear cardiac imaging and Positron is already working with the industry’s top radiopharmaceutical manufacturers to begin the distribution of their radiopharmaceuticals using the technology. Analysts believe Positron will generate extraordinary revenues selling radiopharmaceutical consumables to the large customer base that exists today for SPECT radiopharmaceuticals (7,000+ opportunities) and will leverage the same base as the SPECT industry migrates to PET as the #1 cardiac imaging modality in the world. Positron Corp 0.23 -0.02 (-9.27%) Intraday 3 Month 6 Month 1 Year Positron has now entered the execution and growth stage and they are uniquely positioned to be the leader in nuclear cardiology imaging. It is very safe to say that this could be one of our biggest picks of the new year and I urge you to think carefully before trading in and out of this stock too quickly. The share structure is sound, and we have seen this stock trade up very quickly on relatively little volume. In addition to the stability of the company and their pending developments, we are assured that there are no planned warrant exercises or financing mechanisms which will get in the way or dilute shares. That should ease investors' nerves if shares start to climb as rapidly as we anticipate they might within the next few days.

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

To: atm_prophet who wrote (3782)	5/14/2010 7:51:51 PM
From: atm_prophet	of 4096

HERE IS THE DEAL ON NBS (Closed today At $3.45) From: atm_prophet 5/14/2010 7:46:23 PM of 97758 *NBS* READ THIS!!!! I first alerted this board about NBS at $1.95 about a month or so ago. Today it closed over $3.42 But, this could be just the beginning. My advice is to BUY on Monday at the open. Here's Why: Speculation during the past couple of weeks that something big involving their VSELTM technology is about to take place. It's only logical to assume that now that the company has announced an upcoming press conference at NASDAQ MarketSite in New York City on Tuesday, May 25, 2010, 1:00 pm EDT. The company is big on these "very small embryonic like stem cells" which have many of the physical characteristics found in embryonic stem cells, including the ability to differentiate into specialized cells and tissue throughout the bodyeach person has a population of very primitive embryonic-like stem cells that can be harvested for potential therapeutic use. All indications are that this is going to be big news that has the potential to grab lots of headlines, so be prepared. The stock may start to move as soon as Monday, which is why we're issuing this alert to our members now and to our general readership later this afternoon. Already we've seen shares gaining some momentum in the past couple of weeks, but there is much more room to run. good luck to all, Ted ;)

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.